{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:50:40Z","timestamp":1793213440258,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jjcc.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:24:18Z","timestamp":1784647458000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Uric acid and heart failure"],"prefix":"10.1016","author":[{"given":"Masanari","family":"Kuwabara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo F.G.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Ae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Kohro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Kosami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Kanbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Andres-Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Lanaspa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hisatome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2026.07.009_bb0005","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000509","article-title":"ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0010","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0015","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1253\/circj.CJ-25-0002","article-title":"JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure","volume":"89","author":"Kitai","year":"2025","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0020","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and nutrition examination survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0025","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","article-title":"Japanese guideline for the management of hyperuricemia and gout: second edition","volume":"30","author":"Yamanaka","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00129784-200303050-00001","article-title":"Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention","volume":"3","author":"Gavin","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1253\/circj.CJ-18-1233","article-title":"Gender difference in the association between uric acid and atrial fibrillation","volume":"83","author":"Kuwabara","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000443769","article-title":"Hyperuricemia, cardiovascular disease, and hypertension","volume":"3","author":"Kuwabara","year":"2016","journal-title":"Pulse (Basel)"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0045","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/hy1101.092839","article-title":"Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism","volume":"38","author":"Mazzali","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0050","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0055","doi-asserted-by":"crossref","first-page":"F625","DOI":"10.1152\/ajprenal.00140.2005","article-title":"A causal role for uric acid in fructose-induced metabolic syndrome","volume":"290","author":"Nakagawa","year":"2006","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/biom13101519","article-title":"Exploring the multifaceted nexus of uric acid and health: a review of recent studies on diverse diseases","volume":"13","author":"Kuwabara","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijcard.2010.05.002","article-title":"Hyperuricemia predicts adverse outcomes in patients with heart failure","volume":"151","author":"Hamaguchi","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0075","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCHEARTFAILURE.108.797662","article-title":"Hyperuricemia and incident heart failure","volume":"2","author":"Krishnan","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0080","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0085","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.amjcard.2005.04.007","article-title":"Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese acute coronary syndrome study)","volume":"96","author":"Kojima","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ehf2.14535","article-title":"Uric acid is a biomarker for heart failure, but not therapeutic target: result from a comprehensive meta-analysis","volume":"11","author":"Qin","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0095","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jacc.2015.10.086","article-title":"Causal assessment of serum urate levels in Cardiometabolic diseases through a Mendelian randomization study","volume":"67","author":"Keenan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0100","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/eurjpc\/zwac100","article-title":"Serum urate and heart failure: a bidirectional Mendelian randomization study","volume":"29","author":"Yang","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/HYPERTENSIONAHA.120.16547","article-title":"Urate, blood pressure, and cardiovascular disease: evidence from Mendelian randomization and Meta-analysis of clinical trials","volume":"77","author":"Gill","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0110","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11926-013-0400-9","article-title":"The crystallization of monosodium urate","volume":"16","author":"Martillo","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0115","first-page":"643","article-title":"Revised version of guideline for the management of hyperuricemia and gout","volume":"66","author":"Yamanaka","year":"2008","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0120","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0026-0495(86)90152-6","article-title":"Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate","volume":"35","author":"Anton","year":"1986","journal-title":"Metabolism"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0125","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1161\/HYPERTENSIONAHA.116.08998","article-title":"Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study","volume":"69","author":"Kuwabara","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0130","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1186\/ar2519","article-title":"Menopause, postmenopausal hormone use and serum uric acid levels in US women--the Third National Health and Nutrition Examination Survey","volume":"10","author":"Hak","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0135","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1378\/chest.122.5.1686","article-title":"Tissue hypoxia in sleep apnea syndrome assessed by uric acid and adenosine","volume":"122","author":"Saito","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0140","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/s41440-023-01331-w","article-title":"Overnight changes in uric acid, xanthine oxidoreductase and oxidative stress levels and their relationships with sleep-disordered breathing in patients with coronary artery disease","volume":"46","author":"Shimizu","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0145","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/01.CIR.73.3.396","article-title":"Renal function and urate metabolism in late survivors with cyanotic congenital heart disease","volume":"73","author":"Ross","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0150","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1073\/pnas.78.11.6858","article-title":"Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis","volume":"78","author":"Ames","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0155","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cardfail.2020.08.015","article-title":"Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors","volume":"26","author":"Packer","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0160","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1161\/01.CIR.0000041431.57222.AF","article-title":"Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase","volume":"106","author":"Landmesser","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0165","doi-asserted-by":"crossref","first-page":"40732","DOI":"10.1074\/jbc.M112.399899","article-title":"Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver","volume":"287","author":"Lanaspa","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/VHRM.S115080","article-title":"An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia","volume":"13","author":"Bove","year":"2017","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0175","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1093\/eurheartj\/ehv305","article-title":"Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications","volume":"36","author":"Munzel","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/01.CIR.0000022140.61460.1D","article-title":"Allopurinol improves endothelial dysfunction in chronic heart failure","volume":"106","author":"Farquharson","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0185","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11739-013-1016-9","article-title":"Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella heart study","volume":"9","author":"Cicero","year":"2014","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0190","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/eurheartj\/ehq473","article-title":"Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data","volume":"32","author":"Filippatos","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0195","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.amjcard.2014.09.008","article-title":"Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial)","volume":"114","author":"Vaduganathan","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.metabol.2018.02.007","article-title":"Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: a post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo studio della Sopravvivenza nella Insufficienza Cardiaca-heart failure) trial","volume":"83","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jjcc.2025.01.010","article-title":"Prognostic values of proteinuria in patients with acute heart failure","volume":"86","author":"Akama","year":"2025","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0210","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jama.2022.11390","article-title":"Association between gout flare and subsequent cardiovascular events among patients with gout","volume":"328","author":"Cipolletta","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0215","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0225","article-title":"Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: a nationwide cohort study from Japan","volume":"9","author":"Akashi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0230","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: a population-based cohort study","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0235","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcme.2015.07.001","article-title":"Effects of febuxostat and allopurinol on the inflammation and cardiac function in chronic heart failure patients with hyperuricemia","volume":"8","author":"Nakagomi","year":"2015","journal-title":"IJC Metabolic & Endocrine"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/heart.87.3.229","article-title":"Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study","volume":"87","author":"Struthers","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0245","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0250","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11739-019-02070-y","article-title":"Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients","volume":"14","author":"Cicero","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0255","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/hrt.2004.040477","article-title":"Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure","volume":"91","author":"Gavin","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0260","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cardfail.2006.05.005","article-title":"The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata study","volume":"12","author":"Cingolani","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0265","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","article-title":"High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid","volume":"114","author":"George","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0270","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0275","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/0975-3583.74262","article-title":"Allopurinol and global left myocardial function in heart failure patients","volume":"1","author":"Nasr","year":"2010","journal-title":"J Cardiovasc Dis Res"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0280","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604","article-title":"Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study","volume":"3","author":"Ogino","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0285","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.healun.2010.10.003","article-title":"Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters","volume":"30","author":"Greig","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0290","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for Hyperuricemic heart failure patients (EXACT-HF) study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0295","first-page":"756","article-title":"Allopurinol ameliorates cardiac function in non-hyperuricaemic patients with chronic heart failure","volume":"20","author":"Xiao","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261445","article-title":"Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: a prospective, randomized, open-label, blinded-end-point clinical trial","volume":"17","author":"Sakuma","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0305","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/03007995.2023.2223916","article-title":"Uric acid-lowering therapy with benzbromarone in hypertension with asymptomatic hyperuricemia: a randomized study focusing left ventricular diastolic function","volume":"39","author":"Ke","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0310","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00380-024-02448-9","article-title":"Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study","volume":"40","author":"Yokota","year":"2025","journal-title":"Heart Vessel"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0315","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0320","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2016.02.015","article-title":"Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia","volume":"69","author":"Kojima","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0325","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for cerebral and CaRdiorenovascular events PrEvEntion StuDy","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0330","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/CIRCULATIONAHA.118.037976","article-title":"Letter by Kuwabara regarding article, \u201cassessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study\u201d","volume":"139","author":"Kuwabara","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0335","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0340","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0345","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/art.40583","article-title":"New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated Food and Drug Administration public safety alert","volume":"70","author":"Choi","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0350","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/art.40744","article-title":"Febuxostat does not increase all-cause mortality and cardiovascular mortality compared with placebo: comment on the article by Choi et al","volume":"71","author":"Kuwabara","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0360","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41440-022-01116-7","article-title":"Optimal uric acid reduction to improve vascular endothelial function in patients with chronic heart failure complicated by hyperuricemia","volume":"46","author":"Naganuma","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0365","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/art.40914","article-title":"Excess deaths upon cessation of xanthine oxidase inhibitor treatment-data from the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial: comment on the article by Choi et al.","volume":"71","author":"Bubb","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0370","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/art.41066","article-title":"Xanthine oxidase inhibitor withdrawal syndrome? Comment on the article by Choi et al","volume":"71","author":"Johnson","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0375","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jchf.2015.03.008","article-title":"Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis","volume":"3","author":"Prins","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0380","article-title":"Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome","volume":"14","author":"Kuwabara","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0385","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archinternmed.2010.198","article-title":"Gout, allopurinol use, and heart failure outcomes","volume":"170","author":"Thanassoulis","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0390","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0395","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/jamainternmed.2025.7453","article-title":"Treat-to-target urate-lowering treatment and cardiovascular outcomes in patients with gout","volume":"186","author":"Cipolletta","year":"2026","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0400","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001015","article-title":"Failure to reach uric acid target of <0.36 mmol\/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality","volume":"5","author":"Perez Ruiz","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0405","article-title":"Anti-gout medications and risk of cardiovascular disease: a nested case-control study","volume":"8","author":"Chuang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0410","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0304-3940(93)90308-8","article-title":"Distance- and error-related discharge of cells in premotor cortex of rhesus monkeys","volume":"153","author":"Flament","year":"1993","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0415","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12883-016-0692-2","article-title":"Allopurinol and the risk of stroke in older adults receiving medicare","volume":"16","author":"Singh","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0420","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1006\/jmcc.2000.1240","article-title":"Enhanced expression and activity of xanthine oxidoreductase in the failing heart","volume":"32","author":"de Jong","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0425","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1113\/jphysiol.2003.055913","article-title":"Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications","volume":"555","author":"Berry","year":"2004","journal-title":"J Physiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0430","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1053\/j.ajkd.2003.12.023","article-title":"Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek atorvastatin and coronary-heart-disease evaluation (GREACE) study","volume":"43","author":"Athyros","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0435","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.1056","article-title":"Sacubitril\/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF","volume":"20","author":"Mogensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0440","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study","volume":"344","author":"Choi","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0445","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(10)60473-4","article-title":"High-dose versus low-dose losartan in patients with heart failure","volume":"375","author":"Kang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0455","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0460","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"JJV","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0465","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0470","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0475","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.hrthm.2014.04.003","article-title":"Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis","volume":"11","author":"Tamariz","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0480","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijcard.2016.11.268","article-title":"Hyperuricemia is an independent competing risk factor for atrial fibrillation","volume":"231","author":"Kuwabara","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0485","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2018.03.045","article-title":"Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan","volume":"261","author":"Kuwabara","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2026.07.009_bb0490","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000464260","article-title":"Elevated serum uric acid level predicts rapid decline in kidney function","volume":"45","author":"Kuwabara","year":"2017","journal-title":"Am J Nephrol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508726001425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508726001425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:26:06Z","timestamp":1785529566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508726001425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":96,"alternative-id":["S0914508726001425"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2026.07.009","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uric acid and heart failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese College of Cardiology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}